Loerop James 4/A

What Happened

• James Loerop, Chief Business Officer of Aclaris Therapeutics (ACRS), had 15,980 shares withheld by the company on Feb 1, 2025 to satisfy tax withholding obligations related to the vesting/settlement of restricted stock units. The shares were valued at $2.48 each for a total of about $39,630. The transaction is reported as code F (tax withholding/disposition), not an open-market sale.

Key Details

• Transaction date: 2025-02-01; reported in an amended Form 4 filed Feb 3, 2026 (Accession 0001781549-26-000005).
• Price/value: 15,980 shares × $2.48 = $39,630 (approx.).
• Shares owned after transaction: Not specified in the provided summary; the amendment footnote says the corrected withholding number will affect reported beneficial ownership in subsequent filings.
• Footnotes: F1 confirms issuer withheld shares to satisfy tax withholding on RSU vesting. F2 states this is an amendment to correct the number of shares withheld.
• Filing status: Amended Form 4; check later filings for updated beneficial ownership. This disposition is routine tax withholding rather than a discretionary sale.

Context

• Withholding shares to cover taxes on vested RSUs is a common administrative step and does not necessarily indicate insider sentiment about the stock. It reduces the insider’s reported share count but is distinct from a market sale or purchase.